Across TCGA pan-cancer cohorts, CROCC2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CROCC2 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CROCC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CROCC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LUAD, and UCEC are the cancer types where CROCC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.845	0.290	.003	47	view →
LUAD	DFS	Quartile	II,III,IV	0.738	1.000	.022	6	view →
UCEC	OS	Quartile	II,III,IV	0.609	1.000	.043	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CROCC2 tumor-vs-normal RNA expression · all CROCC2 data types